and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

(c)2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals$(R)$, Illuccix(R), ARTMS(R) and QIS$(TM)$ names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates -- all rights reserved.

__________________________

(1) Positron emission tomography.

(2) Single-photon emission computed tomography.

(3) Good Manufacturing Practice.

(4) Financial year ended 31 December 2023.

(5) Telix ASX disclosure 20 December 2021.

(6) Telix ASX disclosure 2 November 2021.

(7) Telix ASX disclosure 14 October 2022.

(END) Dow Jones Newswires

September 22, 2024 18:59 ET (22:59 GMT)